Abstract. Adiponectin is a hormone secreted by adipose tissue and has a variety of functions including the inhibition of tumor growth. The expression and function of the two major adiponectin receptors, AdipoR1 and AdipoR2, in malignant tissue have not been well characterized. In the present study, we evaluated the mRNA levels of AdipoR1 and AdipoR2 expression in 48 surgically resected colorectal cancer specimens, as well as normal colonic mucosa, by quantitative RT-PCR. The values obtained were standardized by β-actin mRNA, and the correlation between their relative expression levels and the clinicopathological characteristics of the patients was examined. The relative expression levels of AdipoR1 and AdipoR2 were significantly reduced in cancer tissue compared with normal tissue (AdipoR1: 0.97±0.39 vs. 1.37±0.41, P<0.0001; AdipoR2: 0.92±0.31 vs. 1.60±0.46, P<0.0001). AdipoR1 and AdipoR2 levels were further reduced in tumors with nodal metastases and the difference was statistically significant in the case of AdipoR2 (0.79±0.27 vs. 1.02±0.30, P=0.012). The results of this study demonstrated that the expression levels of adiponectin receptors are reduced in cancer specimens compared to normal tissue, indicating a downregulation in the course of the development and progression of colorectal cancer. Since adiponectin is abundantly present in the whole body and has inhibitory effects on cancer cells, this downregulation of the receptors may be an escape mechanism of malignant cells from the suppressive effects of adiponectin.
Introduction
Obesity not only increases the risk of insulin resistance or cardiovascular diseases, but has also been identified as a risk factor for various forms of cancer, including breast, endometrial, colon and rectal, kidney, pancreatic, biliary, ovarian, cervical, liver and prostate cancer (1, 2) . Several biological mechanisms have been proposed to explain the risk of cancer in obesity, including the secretion of steroid hormones, insulin, insulin-like growth factors and adipokines (3) (4) (5) .
It is known that adipose tissue is not only a fat-storing tissue but also the largest endocrine organ in the body, producing various cytokines including adiponectin (6) . Adiponectin, also known as gelatin-binding protein-28 (GPD28), AdipoQ, or ACRP30, is a peptide hormone secreted exclusively by adipocytes (7) , and has been shown to have suppressive effects on tumor development (8) (9) (10) . Adiponectin is usually abundant in human plasma, with concentrations ranging from 5 to 30 µg/ml and accounting for up to 0.05% of total plasma protein (11) . Plasma concentrations of adiponectin are known to be inversely correlated with the risk of various cancers, including gastric (12) , breast (13, 14) , prostate (15, 16) , endometrial (17, 18) and renal cell carcinoma (19) . This evidence strongly suggests a potential suppressive role of adiponectin on the development of various types of cancer, particularly in obesity-related carcinogenesis.
The adiponectin receptor exists in two isoforms; adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) (20) . In mice, AdipoR1 is abundantly expressed in skeletal muscle, whereas AdipoR2 is predominantly expressed in the liver (20) . In humans, AdipoR1 and AdipoR2 have been reported to be expressed in adipocytes (21) , skeletal muscle cells (22) , vascular smooth muscle cells, macrophages (23) , pancreatic β cells (24) and liver (25, 26) . The expression of adiponectin receptors has also been reported in various cancer tissues (27) (28) (29) (30) (31) (32) , although the results are still controversial, and the role of the receptor expression in tumor tissues remains to be elucidated.
In a previous study by Otani et al (39) , using quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical staining, it was demonstrated that the expression of AdipoR2 was significantly decreased in gastric cancer tissues compared to normal colorectal tissue. In addition, AdipoR1 levels tended to be decreased.
In the present study, we aimed to examine the expression levels of AdipoR1 and AdipoR2 in human colorectal cancer Cancer and normal tissue samples were obtained from surgically removed specimens in the operating room using a surgical knife. The samples were rapidly submerged in RNAlater RNA stabilization reagent (Qiagen, Hilden, Germany) and stored at 4˚C overnight. The samples were then stored in a freezer at below -20˚C until analysis. This study was conducted with the approval of the Ethics Committee of the University of Tokyo.
Clinicopathological analysis. The following clinicopathological characteristics were evaluated according to the expression of AdipoR1 and AdipoR2: Gender, age, body mass index, tumor location, postoperative histological lymph node metastasis, depth of wall invasion, grade of differentiation, lymphovascular invasion status and UICC (Union for International Cancer Control) stage of the resected cancer specimens.
Quantitative RT-PCR. The sample tissues were homogenized, and the total mRNA was extracted following the manufacturer's instructions using the RNeasy mini kit (Qiagen). The concentrations of the total mRNA samples obtained were measured using a GeneQuant RNA/DNA calculator (Pharmatica GE Healthcare Bio-Sciences, Tokyo, Japan). Reverse transcription was performed using 1 µg of total mRNA, and cDNA was prepared using a High-Capacity cDNA reverse transcription kit (Applied Biosystems Japan, Tokyo), according to the manufacturer's instructions. Real-time PCR assays of AdipoR1 and AdipoR2 mRNA expression levels were performed using the 7500 Fast Real-Time PCR system (Applied Biosystems Japan) and the reagents of TaqMan Fast Universal PCR Master mix (2X) (Applied Biosystems Japan), according to the manufacturer's instructions. The primers of AdipoR1 and AdipoR2 were products of Applied Biosystems (Foster City, CA, USA), and the assay IDs in TaqMan gene expression assays were Hs00360422_m1 and Hs00226105_m1, respectively. The level of adiponectin receptor gene expression was calculated from the standard curve, and quantitative normalization of cDNA in each sample was performed using the expression of the β-actin gene (primer: TaqMan Endogenous Control Human ACTB, Applied Biosystems) as an internal control.
Statistical analysis. Statistical analyses were performed with JMP8.0 (SAS Institute, Cary, NJ, USA). The correlation between the clinicopathological factors and the expression levels of adiponectin receptors was assessed using the nonparametric Wilcoxon rank sum tests or the Kruskal-Wallis test. P<0.05 was considered to indicate a statistically significant result.
Results

Clinicopathological characteristics of the patients and the expression of AdipoR1 and AdipoR2 in normal colorectal
mucosa. The clinicopathological parameters of the 48 patients included in the study and the mRNA expression of adiponectin receptors in the normal mucosa of the resected colorectal cancer specimens are shown in Table I . The samples expressed significant mRNA levels of AdipoR1 and AdipoR2. AdipoR2 was expressed at relatively higher levels than AdipoR1, but the expression levels of AdipoR1 and AdipoR2 did not show a significant correlation with age, gender or body mass index (BMI). Notably, however, the expression levels of both AdipoR1 and AdipoR2 were significantly higher in colonic compared to rectal mucosa (AdipoR1: 
Discussion
Numerous studies have suggested that adiponectin has suppressive effects on cancer development and progression Relative mRNA levels were examined against the internal control (β-actin) with quantitative RT-PCR, and P-values were evaluated with the Wilcoxon rank sum tests. a P<0.05. MP, muscularis propria; SS, subserosa.
(33). The direct inhibitory effect of adiponectin on the growth of colorectal cancer cells (34, 35) , suggestive of the expression of functional adiponectin receptors in colorectal cancer cells, has been demonstrated, and previous studies using human specimens have provided evidence that AdipoR1 and AdipoR2 are expressed in colorectal cancer tissue at mRNA and protein levels (31, 36, 37) .
In the present study, we also confirmed the expression of AdipoR1 and AdipoR2 in colorectal cancer tissues at the mRNA level. These receptors were also expressed in the normal colonic mucosa at the mRNA level. However, compared to normal epithelium, their expression levels were significantly decreased in cancer specimens. This result is consistent with the results found in prostate (38) and gastric cancer (39). However, the expression level of adiponectin receptors in human colorectal cancer tissue remains controversial. Using immunohistochemistry, Williams et al (31) reported that both AdipoR1 and AdipoR2 are expressed in most colorectal carcinomas but not in normal colorectal tissue. Conversely, although not comparing normal and cancerous tissues from the same patients, Yoneda et al (36) reported that the two isoforms of adiponectin receptors were expressed in colorectal cancer cells at the same levels as in normal colonic epithelium. In the present study, therefore, the expression levels of AdipoR1 and AdipoR2 in human colorectal cancer specimens were compared with those in their normal counterparts, and both were significantly decreased in cancer tissues. Additionally, results of an analysis of the correlation of adiponectin receptor expression with clinicopathological parameters of the patients revealed that AdipoR2 mRNA expression was lower in tumors with lymph node metastasis than in those without.
Using immunohistochemistry, Byeon et al reported that AdipoR1 and AdipoR2 expression levels inversely correlated with the T stage (37) . These authors also found that AdipoR2 expression inversely correlated with the AJCC (American Joint Committee on Cancer) stage and the status of lymphovascular invasion. Their findings together with those of this study led to the hypothesis that receptor downregulation in colorectal cancer would be beneficial for the growth of cancer cells in metastatic sites, particularly lymph nodes, and could facilitate the development of nodal metastasis.
Another notable finding in the present study was the significantly lower expression of AdipoR1 and AdipoR2 in the normal mucosa of the rectum than in that of the colon. The mRNA levels of AdipoR1 and AdipoR2 in mucosal tissues of the stomach or small intestine evaluated by the same method were similar to those of the rectum (40) . Therefore, compared to the rest of the gastrointestinal tract, colonic mucosa apparently expresses higher levels of adiponectin receptor. Since colonic epithelia have specific functions as well as different kinetics compared to those of the rest of the gastrointestinal tract (41, 42) , our data suggest the possibility of a relevant physiological function of adiponectin receptors in the colonic mucosa, and further studies are required to elucidate this hypothesis.
The finding in our study of the decreased expression of adiponectin receptors in colorectal cancer compared to their normal counterparts is not in concordance with previous studies (36) . This discrepancy may be attributed to the different samples investigated and the different methodologies applied. Since adiponectin is known to inhibit the growth of colorectal cancer cells, our data support the hypothesis that the downregulation of AdipoR1 and AdipoR2 expression in colorectal epithelium may have a protective role in colorectal carcinogenesis.
In conclusion, we have demonstrated that the two major receptors for adiponectin, AdipoR1 and AdipoR2, were downregulated in colorectal cancer, and particularly decreased in tumors with lymph node metastasis. To the best of our knowledge, this is the first study to demonstrate the inverse correlation between adiponectin receptor expression and colorectal carcinogenesis and nodal metastasis. Since adiponectin is abundantly present in the human circulation, the downregulation of its receptor may be an escape mechanism of malignant cells against the suppressive effect of adiponectin in the course of cancer development and metastasis. 
